# Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome

Source: https://onco.cc/trials/nct05673057/  
OnCo record `nct05673057` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Azacitidine, Venetoclax and Obinutuzumab in acute myeloid leukaemia, run by Molecular Partners AG, active and no longer recruiting.

## Summary

Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome is a phase 1/2 interventional study registered as NCT05673057 by Molecular Partners AG, with 249 participants enrolled, started 2022-12-29 and due to reach its primary completion in 2026-05-29. Interventions recorded: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax, MP0533 with Obinutuzumab pretreatment, MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML and MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05673057
- Phase: 1/2
- Setting: A Phase 1/2a, First-in-human, Open-label, Multicenter, Dose Escalation Study of MP0533 in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Sponsor: Molecular Partners AG
- Enrolled: 249

## Sources

- ClinicalTrials.gov NCT05673057: https://clinicaltrials.gov/study/NCT05673057

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Obinutuzumab](https://onco.cc/drugs/obinutuzumab/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [Molecular Partners](https://onco.cc/companies/molecular-partners/)

---
JSON: https://onco.cc/api/v1/entities/nct05673057.json